Pre-made Galiximab benchmark antibody ( Whole mAb, anti-CD80 therapeutic antibody, Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009, it is undergoing Phase III clinical trials. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
| Products Name (INN Index) | Pre-Made Galiximab biosimilar, Whole mAb, Anti-CD80 Antibody: Anti-B7/BB1/B7-1/B7.1/LAB7/CD28LG/CD28LG1 therapeutic antibody |
|---|---|
| INN Name | Galiximab |
| Target | CD80 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2003 |
| Year Recommended | 2004 |
| Companies | Biogen,Biogen Idec |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Autoimmune disorders,Non-Hodgkin's lymphoma,Psoriasis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD80 |
| Package |
